

# **Anti retroviral Drugs Market Size, Trends, Analysis, and Outlook By Drug Class (Protease Inhibitors, Integrase Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Others), by Country, Segment, and Companies, 2024-2032**

<https://marketpublishers.com/r/AFF8D932F3EAEN.html>

Date: April 2024

Pages: 205

Price: US\$ 3,980.00 (Single User License)

ID: AFF8D932F3EAEN

## **Abstracts**

The global Anti retroviral Drugs market size is poised to register 4.8% growth from 2024 to 2032, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Anti retroviral Drugs market across By Drug Class (Protease Inhibitors, Integrase Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Others)

With the ongoing global HIV/AIDS epidemic and the increasing focus on achieving universal access to antiretroviral therapy (ART), there is a rising need for effective anti-retroviral drugs that suppress viral replication, prevent transmission, and improve long-term outcomes in patients living with HIV/AIDS. Market growth is driven by factors such as expanding HIV testing and treatment programs, the rising prevalence of HIV/AIDS in low- and middle-income countries, and technological advancements in drug development and drug delivery. Additionally, the expanding applications of anti-retroviral drugs in HIV prevention and pre-exposure prophylaxis (PrEP), as well as the growing adoption of multi-drug combination regimens and long-acting formulations, contribute to market expansion. Further, the development of novel drug classes and drug resistance testing assays, the integration of ART into integrated health systems and community-based care models, and the emphasis on global partnerships and funding initiatives are

expected to further propel market growth in the coming years.

## Anti retroviral Drugs Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Anti retroviral Drugs market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Anti retroviral Drugs survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Anti retroviral Drugs industry.

## Key market trends defining the global Anti retroviral Drugs demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

## Anti retroviral Drugs Market Segmentation- Industry Share, Market Size, and Outlook to 2032

The Anti retroviral Drugs industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Anti retroviral Drugs companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

## Key strategies adopted by companies within the Anti retroviral Drugs industry

Leading Anti retroviral Drugs companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Anti retroviral Drugs companies.

## Anti retroviral Drugs Market Study- Strategic Analysis Review

*Anti retroviral Drugs Market Size, Trends, Analysis, and Outlook By Drug Class (Protease Inhibitors, Integrase...*

The Anti retroviral Drugs market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

**Industry Dynamics:** Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

**Strategic Insights:** Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

**Internal Strengths and Weaknesses:** Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

**Future Possibilities:** Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

### Anti retroviral Drugs Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Anti retroviral Drugs industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.

### Anti retroviral Drugs Country Analysis and Revenue Outlook to 2032

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2032.

### North America Anti retroviral Drugs Market Size Outlook- Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare

infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to \$4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Anti retroviral Drugs market segments. Similarly, Strong market demand is encouraging Canadian Anti retroviral Drugs companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Anti retroviral Drugs market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Anti retroviral Drugs Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Anti retroviral Drugs industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Anti retroviral Drugs market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Anti retroviral Drugs Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Anti retroviral Drugs in Asia Pacific. In particular, China, India, and South East Asian Anti retroviral Drugs markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.

Latin America Anti retroviral Drugs Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Anti retroviral Drugs Market Size Outlook- continues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Anti retroviral Drugs market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Anti retroviral Drugs.

Anti retroviral Drugs Market Company Profiles

The global Anti retroviral Drugs market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are AbbVie Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc, F. Hoffmann-La Roche AG, Gilead Sciences Inc, GlaxoSmithKline plc, Johnson and Johnson, Merck & Co Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Viartis Inc.

Recent Anti retroviral Drugs Market Developments

The global Anti retroviral Drugs market study presents recent market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Anti retroviral Drugs Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local Currency)

## Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

## Market Segmentation:

By Drug Class

Protease Inhibitors

Integrase Inhibitors

Multi-class Combination Products

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Others

## Geographical Segmentation:

North America (3 markets)

Europe (6 markets)

Asia Pacific (6 markets)

Latin America (3 markets)

Middle East Africa (5 markets)

## Companies

AbbVie Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

Cipla Inc

F. Hoffmann-La Roche AG

Gilead Sciences Inc

GlaxoSmithKline plc

Johnson and Johnson

Merck & Co Inc

Pfizer Inc

Teva Pharmaceutical Industries Ltd

Viartis Inc

Formats Available: Excel, PDF, and PPT

## Contents

### 1. EXECUTIVE SUMMARY

- 1.1 Anti retroviral Drugs Market Overview and Key Findings, 2024
- 1.2 Anti retroviral Drugs Market Size and Growth Outlook, 2021- 2030
- 1.3 Anti retroviral Drugs Market Growth Opportunities to 2030
- 1.4 Key Anti retroviral Drugs Market Trends and Challenges
  - 1.4.1 Anti retroviral Drugs Market Drivers and Trends
  - 1.4.2 Anti retroviral Drugs Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Anti retroviral Drugs Companies

### 2. ANTI RETROVIRAL DRUGS MARKET SIZE OUTLOOK TO 2030

- 2.1 Anti retroviral Drugs Market Size Outlook, USD Million, 2021- 2030
- 2.2 Anti retroviral Drugs Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

### 3. ANTI RETROVIRAL DRUGS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
  - \* Threat of New Entrants
  - \* Threat of Substitutes
  - \* Intensity of Competitive Rivalry
  - \* Bargaining Power of Buyers
  - \* Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

### 4. ANTI RETROVIRAL DRUGS MARKET SEGMENTATION ANALYSIS AND OUTLOOK

- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030
  - By Drug Class
    - Protease Inhibitors
    - Integrase Inhibitors



Multi-class Combination Products

Nucleoside Reverse Transcriptase Inhibitors (NRTIs)

Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

Others

4.3 Growth Prospects and Niche Opportunities, 2023- 2030

4.4 Regional comparison of Market Growth, CAGR, 2023-2030

## **5. REGION-WISE MARKET OUTLOOK TO 2030**

5.1 Key Findings for Asia Pacific Anti retroviral Drugs Market, 2025

5.2 Asia Pacific Anti retroviral Drugs Market Size Outlook by Type, 2021- 2030

5.3 Asia Pacific Anti retroviral Drugs Market Size Outlook by Application, 2021- 2030

5.4 Key Findings for Europe Anti retroviral Drugs Market, 2025

5.5 Europe Anti retroviral Drugs Market Size Outlook by Type, 2021- 2030

5.6 Europe Anti retroviral Drugs Market Size Outlook by Application, 2021- 2030

5.7 Key Findings for North America Anti retroviral Drugs Market, 2025

5.8 North America Anti retroviral Drugs Market Size Outlook by Type, 2021- 2030

5.9 North America Anti retroviral Drugs Market Size Outlook by Application, 2021- 2030

5.10 Key Findings for South America Anti retroviral Drugs Market, 2025

5.11 South America Pacific Anti retroviral Drugs Market Size Outlook by Type, 2021- 2030

5.12 South America Anti retroviral Drugs Market Size Outlook by Application, 2021- 2030

5.13 Key Findings for Middle East and Africa Anti retroviral Drugs Market, 2025

5.14 Middle East Africa Anti retroviral Drugs Market Size Outlook by Type, 2021- 2030

5.15 Middle East Africa Anti retroviral Drugs Market Size Outlook by Application, 2021- 2030

## **6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030**

6.1 US Anti retroviral Drugs Market Size Outlook and Revenue Growth Forecasts

6.2 US Anti retroviral Drugs Industry Drivers and Opportunities

6.3 Canada Market Size Outlook and Revenue Growth Forecasts

6.4 Canada Anti retroviral Drugs Industry Drivers and Opportunities

6.6 Mexico Market Size Outlook and Revenue Growth Forecasts

6.6 Mexico Anti retroviral Drugs Industry Drivers and Opportunities

6.7 Germany Market Size Outlook and Revenue Growth Forecasts

6.8 Germany Anti retroviral Drugs Industry Drivers and Opportunities

6.9 France Market Size Outlook and Revenue Growth Forecasts

- 6.10 France Anti retroviral Drugs Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Anti retroviral Drugs Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Anti retroviral Drugs Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Anti retroviral Drugs Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Anti retroviral Drugs Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Anti retroviral Drugs Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Anti retroviral Drugs Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Anti retroviral Drugs Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Anti retroviral Drugs Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Anti retroviral Drugs Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Anti retroviral Drugs Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Anti retroviral Drugs Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Anti retroviral Drugs Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Anti retroviral Drugs Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Anti retroviral Drugs Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Anti retroviral Drugs Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Anti retroviral Drugs Industry Drivers and Opportunities

## **7. ANTI RETROVIRAL DRUGS MARKET OUTLOOK ACROSS SCENARIOS**

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

## **8. ANTI RETROVIRAL DRUGS COMPANY PROFILES**

8.1 Profiles of Leading Anti retroviral Drugs Companies in the Market

8.2 Business Descriptions, SWOT Analysis, and Growth Strategies

8.3 Financial Performance and Key Metrics

AbbVie Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Company

Cipla Inc

F. Hoffmann-La Roche AG

Gilead Sciences Inc

GlaxoSmithKline plc

Johnson and Johnson

Merck & Co Inc

Pfizer Inc

Teva Pharmaceutical Industries Ltd

Viartis Inc.

## **9. APPENDIX**

9.1 Scope of the Report

9.2 Research Methodology and Data Sources

9.3 Glossary of Terms

9.4 Market Definitions

9.5 Contact Information

## I would like to order

Product name: Anti retroviral Drugs Market Size, Trends, Analysis, and Outlook By Drug Class (Protease Inhibitors, Integrase Inhibitors, Multi-class Combination Products, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Others), by Country, Segment, and Companies, 2024-2032

Product link: <https://marketpublishers.com/r/AFF8D932F3EAEN.html>

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AFF8D932F3EAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970